Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020.Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50.Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like).The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences. Body fatness is a dynamic exposure throughout life. To provide more insight into the association between body mass index (BMI) and postmenopausal breast cancer, we aimed to examine the age at onset, duration, intensity, and trajectories of body fatness in adulthood in relation to risk of breast cancer subtypes. Based on self-reported anthropometry in the prospective Norwegian Women and Cancer Study, we calculated the age at onset, duration, and intensity of overweight and obesity using linear mixed-effects models. BMI trajectories in adulthood were modeled using group based trajectory modeling. We used Cox proportional hazards models to calculate hazard ratios (HRs) with 95% confidence intervals (Cis) for the associations between BMI exposures and breast cancer subtypes in 148,866 postmenopausal women. Advanced glycation end products (AGEs) are reactive metabolites intrinsically linked with modern dietary patterns. Processed foods, and those high in sugar, protein and fat, often contain high levels of AGEs. Increased AGE levels are associated with increased breast cancer risk, however their significance has been largely overlooked due to a lack of direct cause-and-effect relationship. Immunohistochemistry and immunofluorescence were used to assess cellular proliferation and stromal fibroblast and macrophage recruitment. The Kruskal–Wallis test were used to compare continuous outcomes among groups. Mammary epithelial cell migration and invasion in response to AGE-mediated fibroblast activation was determined in two compartment co-culture models. In vitro experiments were performed in triplicate. The nonparametric Wilcoxon rank sum test was used to compare differences between groups. Deep learning analysis of radiological images has the potential to improve diagnostic accuracy of breast cancer, ultimately leading to better patient outcomes. This paper systematically reviewed the current literature on deep learning detection of breast cancer based on magnetic resonance imaging (MRI). The literature search was performed from 2015 to Dec 31, 2022, using Pubmed. Other database included Semantic Scholar, ACM Digital Library, Google search, Google Scholar, and pre-print depositories (such as Research Square). Articles that were not deep learning (such as texture analysis) were excluded. PRISMA guidelines for reporting were used. We analyzed different deep learning algorithms, methods of analysis, experimental design, MRI image types, types of ground truths, sample sizes, numbers of benign and malignant lesions, and performance in the literature.


Breast cancer


  1. Boyd NF, Connelly P, Byng J, Yafe M, Draper H, Little L, Jones D, Martin LJ, Lockwood G, Tritchler D. Plasma lipids, lipoproteins, and mammographic Densities. Cancer Epidemiol Biomarkers Prev. 1995;4(7):727–33.
  2. Beral V, Million Women Study C. Breast cancer and hormone-Replacement therapy in the Million Women Study. Lancet.2003;362(9382):419–27.
  3. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy And incidence of hormone-dependent cancers in the Norwegian Women And Cancer study. Int J Cancer. 2004;112(1):130–4.
  4. Vinay Kamal Director Professor of Pathology Maulana Azad Medical College Bahadur Shah Zafar Marg New Delhi (India) (Textbook).volume I.
  5. Carayol M, Licaj I, Achaintre D, Sacerdote C, Vineis P, Key TJ, Onland Moret NC, Scalbert A, Rinaldi S, Ferrari P. Reliability of serum metabolites over a Two-year period: a targeted metabolomic approach in fasting and non Fasting samples from EPIC. PLoS ONE. 2015;10(8): e0135437.
  6. Cullinane C, Fleming C, O’Leary DP, et al. Association of Circulating Tumor DNA with disease- Free Survival in Breast Cancer: A Systematic Review and Meta-Analysis.
  7. Cuzick, J et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal Women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet. 2014;383 (9922):1041 – 1048.
  8. Chan JCH, Chow JCH, Ho CHM, Tsui TYM, Cho WC. Clinical application of circulating tumor DNA in breast cancer. J Cancer Res Clin Oncol. 2021;147(5):1431-1442.
  9. Eghlimi R, Shi X, Hrovat J, Xi B, Gu H. Triple negative breast cancer Detection using LC-MS/MS Lipidomic profling. J Proteome Res.2020;19(6):2367–78.
  10. Eiriksson FF, Nohr MK, Costa M, Bodvarsdottir SK, Ogmundsdottir HM,Thorsteinsdottir M. Lipidomic study of cell lines reveals differences Between breast cancer subtypes. PLoS ONE. 2020;15(4): e0231289.
  11. Fitzmaurice GM. Longitudinal data analysis. Boca Raton: CRC Press; 2009.p. xiv, 618.
  12. Giudetti AM, De Domenico S, Ragusa A, Lunetti P, Gaballo A,Franck J, Simeone P, Nicolardi G, De Nuccio F,Santino A, et al.A specifc lipid Metabolic profle is associated with the epithelial mesenchymal transition Program.Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(3):344 - 57.
  13. Giallourou N, Urbaniak C, Puebla-Barragan S, Vorkas PA, Swann JR, Reid G. Characterizing the breast cancer lipidome and its interaction with the Tissue microbiota. Commun Biol. 2021;4(1):1229.
  14. Goss, P.E., et al., Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011. 364(25): p. 2381-2391.
  15. Greene LR, Wilkinson D. The role of general nuclear medicine in breast cancer. J Med Radiat Sci. 2015;62(1):54-65.
  16. Heo M, Faith MS, Mott JW, Gorman BS, Redden DT, Allison DB. Hier -Archical linear models for the development of growth curves: an Example with body mass index in overweight/obese adults. Stat Med.2003;22(11):1911–42.
  17. Henry NL, Bedard PL, and DeMichele A. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. In Dizon DS, Pennel N, Rugo HS, Pickell LF, eds.2017 American Society of Clinical Oncology Educational Book. 53rd Annual Meeting.2017.
  18. Ignatiadis M, Lee M, and Jeffrey SS. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res;21(21); 4786–800.
  19. Jones BL, Nagin DS. Advances in group-based trajectory modeling And an SAS procedure for estimating them. Sociol Methods Res.2007;35(4):542–71.
  20. Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL, et al.Risk factors that increase risk of estrogen receptor-positive and -negative Breast cancer. J Natl Cancer Inst. 2017;109(5):djw276.
  21. Knuplez E, Marsche G: An Updated Review of Pro- and Anti-Infammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System. Int J Mol Sci 2020, 21(12).
  22. Kimura T, Jennings W, Epand RM. Roles of specifc lipid species in the cell And their molecular mechanism. Prog Lipid Res. 2016;62:75–92.
  23. Lodi M, Kiehl A, Qu FL, Gabriele V, Tomasetto C, Mathelin C. Lipid intake And breast cancer risk: is there a link? A new focus and meta-analysis.J Breast Health. 2022;18(2):108–26.
  24. Lunn M, McNeil D. Applying Cox regression to competing risks. Biomet-Rics. 1995;51(2):524–32.
  25. Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019.
  26. Lucht SA, Eliassen AH, Bertrand KA, Ahern TP, Borgquist S, Rosner B,Hankinson SE, Tamimi RM. Circulating lipids, mammographic density, and Risk of breast cancer in the Nurses’ Health Study and Nurses’ Health Study II. Cancer Causes Control. 2019;30(9):943–53.
  27. Mohammadzadeh F, Mosayebi G, Montazeri V, Darabi M, Fayezi S, Shaaker M, Rahmati M, Baradaran B, Mehdizadeh A, Darabi M. Fatty acid completion of tissue cultured breast carcinoma and the efect of Stearoyl-CoA desaturase 1 inhibition. J Breast Cancer. 2014;17(2):136–42.
  28. Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant Treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229.
  29. Mayer IA, Dent R, Tan T, et al. Novel Targeted Agents and Immunotherapy in Breast Cancer. In Dizon DS, Pennel N, Rugo HS, Pickell LF, eds. 2017 American Society of Clinical Oncology Educational Book. 53rd Annual Meeting. 2017.
  30. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in Women. Ann Intern Med. 1985;103(3):350–6.
  31. Nagin DS. Analyzing developmental trajectories: a semiparametric,Group-based approach. Psychol Methods. 1999;4(1):139–57.
  32. National Institute of Environmental Health Sciences. Breast Cancer. Last reviewed November 15, 2021. Accessed January 19, 2022.
  33. Nagin DS. Group-based modeling of development. Cambridge: Harvard University Press; 2005.
  34. Prentice RL, Kalbfeisch JD, Peterson AV Jr, Flournoy N, Farewell VT,Low NE. The analysis of failure times in the presence of competing risks.Biometrics. 1978;34(4):541–54.
  35. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal , HER2- overexpressing, and triple-negative breast cancer in postmenoPausal women. Cancer Epidemiol Biomark Prev. 2008;17(8):2078–86.
  36. Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, et al.Body mass index, mammographic density, and breast cancer risk by Estrogen receptor subtype. Breast Cancer 2019;21(1):48.
  37. Trivers KF, Lund MJ, Porter PL, Lif JM, Flagg EW, Coates RJ, et al. The epideMiology of triple- negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–82.
  38. Thurmer M, Gollowitzer A, Pein H, Neukirch K, Gelmez E, Waltl L, Wielsch N, Winkler R, Loser K, Grander J, et al. PI(18:1/18:1) is a SCD1-derived Lipokine that limits stress signaling. Nat Commun. 2022;13(1):2982.
  39. Vinay Kamal Director Professor of Pathology Maulana Azad Medical College Bahadur Shah Zafar Marg New Delhi (India) (Textbook).volume II.
  40. Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al.Statistical methods for studying disease subtype heterogeneity. Stat Med.2016;35(5):782–800.
  41. Ward AV, Anderson SM, Sartorius CA. Advances in analyzing the breast Cancer lipidome and its relevance to disease progression and treatment. J Mammary Gland Biol Neoplasia. 2021;26(4):399–417.

Hariom Rajput
Corresponding author

GV2C+4M7, Jhanjrola, Haryana 124105

Dr. Mahi Rajput

GV2C+4M7, Jhanjrola, Haryana 124105

Hariom Rajput*, Dr. Mahi Rajput, Breast Cancer, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 11, 245-259.

More related articles
Applications Of Nanotechnology In Cancer Therapy...
Damini G. Sonawane, Pankaj Shirsath, ...
To Study Invitro Anticancer activity Brine shrimp ...
Kaufiya D Sayyad, Ashpak M. Tamboli, Manoj S. Patil, ...
Nanotechnology and its Therapeutic and Cosmetic Ap...
Abhijit Bhosle, Dr. Nayana Baste, ...
Recent Progress In Metal Organic Framework As Drug Delivery Platform...
Sagar A Sarode, Yogesh N Sonawane, Mayuri A Sarode, Parag R Patil, Adityaraj D Kumbhar, Vaishali A P...
Review on Achyranthes aspera...
Ramakrishna S., Ruqiya bi, ...
Related Articles
To Study Antioxidant and Anticancer activity of aqueous extract of Onion peels, ...
Sushant Mane, Sangram Falake, Somnath Mali, Dr. Ashpak Tamboli, ...
An Overview of Her 2 Neu Positive Breast Cancer...
K. Sireesha, P. Shivani Naidu, P. Lakshmi Prasanna, A. Renuka, G. Manas Kumar, ...
Understanding The Role of Molecular Targeted Therapeutic Drugs In Non Small Cell...
Himanshu Singh, Arunee Garg, Nency Parihar, Vedant Patel, Ranjan Mani Tripathi, ...